Gyre Therapeutics, Inc. (GYRE)

NASDAQ: GYRE · IEX Real-Time Price · USD
17.48
-0.05 (-0.29%)
Mar 28, 2024, 4:00 PM EDT - Market closed

Company Description

Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on development and commercialization of liver fibrosis associated with a broad spectrum of chronic liver diseases in the United States and internationally.

It develops Hydronidone, that has completed phase 1 clinical trial for the treatment of nonalcoholic steatohepatitis, a severe form of nonalcoholic fatty liver disease.

The company was founded in 2002 and is headquartered in South San Francisco, California.

Gyre Therapeutics, Inc.
Gyre Therapeutics logo
Country United States
Founded 2002
Industry Biotechnology
Sector Healthcare
Employees 7
CEO Nassim Usman

Contact Details

Address:
12770 High Bluff Drive, Suite 150
San Diego, California 92130
United States
Phone (619) 949-3681
Website gyretx.com

Stock Details

Ticker Symbol GYRE
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001124105
CUSIP Number 14888D109
ISIN Number US14888D2080
Employer ID 56-2020050
SIC Code 2834

Key Executives

Name Position
Dr. Nassim Usman Ph.D. President, Chief Executive Officer and Director
Seline E. Miller CPA Senior Vice President of Finance, Interim Chief Financial and Principal Accounting Officer
Dr. Grant Blouse M.Sc., Ph.D. Chief Scientific Officer
Ana Kapor Senior Director of Investor Relations and Corporate Communications
Dr. Tom Knudsen D.V.M., Ph.D. Senior Vice President of Corporate Development

Latest SEC Filings

Date Type Title
Mar 28, 2024 S-8 Securities to be offered to employees in employee benefit plans
Mar 27, 2024 10-K Annual Report
Mar 26, 2024 8-K Current Report
Mar 26, 2024 8-K Current Report
Mar 21, 2024 8-K Current Report
Mar 15, 2024 144 Filing
Feb 14, 2024 8-K Current Report
Feb 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Jan 24, 2024 SC 13D/A [Amend] General statement of acquisition of beneficial ownership
Jan 19, 2024 8-K/A [Amend] Current report